Egalet Corporation (NASDAQ:EGLT) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Egalet Corporation (NASDAQ:EGLT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On August9, 2017, Egalet Corporation (the “Company”) issued a press release announcing its financial results for its second quarter ended June30, 2017. A copy of that press release and the attached financial schedules are attached as Exhibit99.1 to this report and incorporated herein by reference.

The information included in this Item 2.02 (including Exhibit99.1) is being furnished to Item 2.02 and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNumber

Description

99.1

Press Release, dated August9, 2017, announcing financial results for the second quarter ended June30, 2017.


Egalet Corp Exhibit
EX-99.1 2 a17-19909_1ex99d1.htm EX-99.1 EXHIBIT 99.1   Egalet Announces Second Quarter 2017 Financial Results and Expense Reduction Plan —Revenue increased 81% year over year and 15% over first quarter— —Company restructuring expected to reduce costs by 35%— —Company to host conference call today at 4:30 PM ET —   Wayne,…
To view the full exhibit click here

About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.